Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | ATM | Q13315 | 3/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30694876 | 0.78 | CHRNB4 (0.36) | SYK | |
| SCHEMBL21590964 | 0.75 | PDE3B (0.38) | PDE3BPDE3A | |
| SCHEMBL30961923 | 0.73 | POLB (0.46) | MAPTALDH1A1HSD17B10KMT2A | |
| SCHEMBL5759446 | 0.72 | ALDH1A1 (0.47) | MAPTALDH1A1KMT2AKDM4E | |
| SCHEMBL1588164 | 0.72 | POLB (0.50) | MAPTRAB9AALDH1A1KMT2AKDM4E | |
| SCHEMBL3704744 | 0.68 | MAPT (0.41) | MAPTRAB9AALDH1A1KMT2AKDM4E | |
| SCHEMBL30961905 | 0.68 | TIPARP (0.51) | MAPTRAB9AALDH1A1KMT2AKDM4E | |
| SCHEMBL5743091 | 0.66 | LMNA (0.46) | MAPTALDH1A1KMT2AATMKDM4E | |
| SCHEMBL31574277 | 0.66 | SYK (0.41) | KDM4ESYK | |
| SCHEMBL21557997 | 0.65 | MAPT (0.45) | MAPTRAB9AALDH1A1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11840528-B2 | Isoxazolyl ether derivatives as GABAA α5 PAM | HOFFMANN-LA ROCHE INC. (US) | 2023-12-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11840528-B2 | Isoxazolyl ether derivatives as GABAA α5 PAM | GABRA5, GABRA2, GABRB2 | MAPT 2899/4885RAB9A 855/4885ALDH1A1 1215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.